TP53 and B-cell chronic lymphocytic leukemia: M-CLL is associated with a considerably longer time-to-first treatment (TTFT) compared with U-CLL.3,4 Other important recurrent molecular drivers are numerous cytogenetic anomalies, including trisomy 12, deletions of chromosome 13q14, 11q22, or 17p13, genomic complexity, and single-gene lesions, most notably affecting the TP53 gene.5–7